NASDAQ:SBFM Sunshine Biopharma Q1 2026 Earnings Report $2.31 +0.09 (+3.83%) As of 03:08 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sunshine Biopharma EPS ResultsActual EPS-$2.50Consensus EPS -$1.60Beat/MissMissed by -$0.90One Year Ago EPSN/ASunshine Biopharma Revenue ResultsActual Revenue$8.09 millionExpected Revenue$9.20 millionBeat/MissMissed by -$1.11 millionYoY Revenue GrowthN/ASunshine Biopharma Announcement DetailsQuarterQ1 2026Date5/13/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsSunshine Biopharma's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sunshine Biopharma Earnings HeadlinesSBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 15 at 1:00 AM | Reagan Gold Group (Ad)Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSunshine Biopharma stock rises after Health Canada approval for DomperidoneOctober 28, 2025 | za.investing.comSunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related NauseaOctober 28, 2025 | finanznachrichten.deSee More Sunshine Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email. Email Address About Sunshine BiopharmaSunshine Biopharma (NASDAQ:SBFM) is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors. Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines. The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.View Sunshine Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big QuestionAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the Show Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
